In the news release, Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice, issued 27-Apr-2010 by Sheller, P.C. over PR Newswire, we are advised by the organization that both references to the Phillip Morris verdict should indicate a $10.1 billion amount, not $10.1 million as originally issued inadvertently. The complete, corrected release follows:
Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
Sheller, P.C. is Primary Counsel for Record-Breaking $520 Million Civil Settlement; Firm Instrumental in Recovering More Than $4.2 Billion in Pharma Settlements in the Last 15 Months
PHILADELPHIA, April 27 /PRNewswire-USNewswire/ -- AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.
The first complaint in the matter was filed on behalf of a whistleblower by qui tam whistleblower, class action, and mass tort attorney Stephen A. Sheller, Esq. of Philadelphia's Sheller, P.C. in 2004.
Sheller and firm partner Brian J. McCormick, Jr., Esq. also represented whistleblowers in previous off-label, failure to warn, and consumer fraud drug investigations, including 2009's Eli Lilly and Pfizer record settlements for $1.4 and $2.3 billion respectively. The Sheller firm has been counsel for whistleblowers in cases that have brought more than $4.2 billion in settlements for the United States government in just the last 15 months.
Sheller is also known for pursuing Phillip Morris for fraud in the $10.1 billion "light" tobacco verdict and is currently mounting a nationwide consumer class action against Toyota.
Seroquel is approved by the U.S. Food and Drug Administration ("FDA") only for schizophrenia and specific types of bipolar mania. AstraZeneca was charged with promoting Seroquel to physicians for use "off-label" in children and the elderly. Doctors are allowed to prescribe drugs for unapproved uses but FDA rules state that drug manufacturers may only promote their products for approved conditions and age groups.
The settlement unsealed today by the U.S. Department of Justice and the U.S. Attorney's Office in Philadelphia indicates marketing practices for Seroquel included promotion of the drug by physicians participating in clinical studies and drug sales representatives encouraging doctors to prescribe for the unapproved uses.
Whistleblowers are protected by the federal False Claims Act, where employees aware of their company knowingly defrauding the government may sue without threat of being fired, harassed, demoted, or discriminated against for cooperating in an investigation of their employer.
"My client showed courage and determination in bringing forth the allegations against AstraZeneca," said Sheller. "As a company employee, he knew alerting the government to the marketing practices potentially put his professional life in jeopardy but he believed protecting public safety and bringing attention to fraud against the government outweighed his personal interests."
Sheller lauded the team in the U.S. Attorney's office for their investigation, including Chief of the Civil Division Virginia Gibson and Assistant U.S. Attorney Colin Cherico. "Once again, the U.S. Attorney's office in Philadelphia came through, supporting whistleblower efforts, recouping hundreds of millions for the government and its citizen taxpayers," said Sheller.
Seroquel is among the top-selling drugs in the world with 2009 sales of $4.9 billion, 15% of AstraZeneca's $33.2 billion in revenue.
About Sheller, P.C.
Sheller P.C. (http://www.Sheller.com) is among the preeminent plaintiff and qui tam whistleblower law firms in the United States. Stephen A. Sheller, Esq., Managing Partner, has been an effective advocate for victims for nearly three decades. Sheller is currently representing large, multi-state classes of Toyota owners nationwide and has litigated groundbreaking cases ranging from tobacco fraud, defective drugs, products liability and whistleblower lawsuits. The firm also practices in complex mass tort and commercial litigation involving business disputes and consumer fraud. Known as the leader of the "Charge of the 'Light Brigade'" Sheller won a $10.1 billion verdict against Phillip Morris for consumer fraud in the marketing of "light" cigarettes. Sheller also initiated the Palm Beach County, Florida litigation involving the 2000 U.S. Presidential election and the "butterfly ballots" which launched him into national media prominence as a lead attorney challenging the voting count. Sheller is frequently interviewed by national media and appears on "The American Law Journal," the television talk program on the law that airs on the Philadelphia CNN-affiliate.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Stephen A. Sheller, Esq.
Brian J. McCormick, Jr., Esq.
SOURCE Sheller, P.C.